RxDoctor Payments Data

Nyla Cooper

Nurse Practitioner · Port Charlotte, FLNPI 1477071330

Payments from drug & device makers

$4,987in general payments, 2019–2025

Across 203 payments — averaging $24.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$902
  • Lilly USA, LLC$568
  • Amgen$384
  • Sanofi-aventis U.S. LLC$379
  • Dexcom, Inc.$375
  • Boehringer Ingelheim$349
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$4,968100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,987 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$96,032
Medicare patients
125
Services billed
1,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide42$34,832
Lagevrio (Eua)Molnupiravir34$34,157
EliquisApixaban73$12,997
Tresiba Flextouch U-100Insulin Degludec21$9,817
LinzessLinaclotide13$7,467
Gabapentin252$5,327
JanuviaSitagliptin Phosphate23$5,207
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen167$4,123
Potassium Chloride69$2,364
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$2,112
Tramadol Hcl132$1,717
Sucralfate11$1,665
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen77$1,544
Esomeprazole Magnesium12$1,500
Mirtazapine34$1,445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckLagevrio (Eua), Januvia$50$39,36457 claims
Lilly USA, LLCTrulicity, Olanzapine$568$35,18653 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Port Charlotte

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →